Oncology Corporate Profile
Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, MD. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for clinical success in genetically defined patient populations.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Loxo-101||tropomyocin receptor kinase A (TrkA) inhibitor||Various cancer types||II|
|Loxo-101||tropomyocin receptor kinase A (TrkA) inhibitor||Sarcoma||I|
View additional information on product candidates here »